Wigen Biomedicine Technology (Shanghai) Co. Ltd. has disclosed fused ring compounds acting as Wee1-like protein kinase (Wee1) inhibitors reported to be useful for the treatment of cancer.

Wigen Biomedicine Technology (Shanghai) Co. Ltd. has described 1,2,4-triazolone derivatives acting as dihydroorotate dehydrogenase (DHODH) inhibitors reported to be useful for the treatment of solid tumors and hematologic blood cancer.

Humanwell Healthcare (Group) Co. Ltd. has identified transcriptional enhancer factor (TEAD) inhibitors reported to be useful for the treatment of cancer.

Shanghai Aryl Pharmtech Co. Ltd. and Zhejiang Hisun Pharmaceutical Co. Ltd. have divulged trideuteromethyl-substituted pyrazino pyrazino quinolinone derivatives acting as deuterated GTPase KRAS (mutant) inhibitors reported to be useful for the treatment of cancer.

Biogen Inc. and C4 Therapeutics Inc. have synthesized proteolysis targeting chimeric (PROTAC) compounds comprising cereblon (CRBN) ligands covalently linked to an IL-1 receptor-associated kinase 4 (IRAK-4)-targeting moiety through a linker.

Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd. has disclosed proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase binding moiety covalently linked to a GTPase KRAS (G12D mutant) targeting moiety reported to be useful for the treatment of cancer.

Kanaph Therapeutics Inc. and Yungjin Pharmaceutical Co., Ltd. have presented tyrosine-protein phosphatase nonreceptor type 11 (PTPN11) inhibitors reported to be useful for the treatment of immunological, cardiovascular, eye disorders, fibrosis, cancer, Noonan syndrome, LEOPARD syndrome and neurofibromatosis type 1.

Newave Pharmaceutical LLC. and Guangzhou Lupeng Pharmaceutical Co., Ltd. have identified isoquinolines acting as epidermal growth factor receptor (EGFR) (mutant) inhibitors reported to be useful for the treatment of cancer, inflammation and autoimmune disease.

Philadelphia University (Jordan) has synthesized 2,4-disubstituted-thieno[2,3-d]pyrimidines acting as prostaglandin G/H synthase 2 (COX-2) inhibitors.

Incyte Corp. has disclosed GTPase KRAS (mutant) inhibitors reported to be useful for the treatment of cancer, inflammatory and immunological disorders.